Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Xavier Jones"'
1
Akademický článek
Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study
Autor: Amanda M. Moore, Zohra Nooruddin, Kelly R. Reveles, Paromita Datta, Jennifer M. Whitehead, Kathleen Franklin, Munaf Alkadimi, Madison H. Williams, Ryan A. Williams, Sarah Smith, Renee Reichelderfer, Ion Cotarla, Lance Brannman, Andrew Frankart, Tiernan Mulrooney, Kristin Hsieh, Daniel J. Simmons, Xavier Jones, Christopher R. Frei
Publikováno v: Current Oncology, Vol 30, Iss 9, Pp 8411-8423 (2023)
Background: Durvalumab is approved for the treatment of adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This real-world study describes patient characteristics and durvalumab treatment patterns (num
Externí odkaz: https://doaj.org/article/a6442eb8f00b41e19dd3661c7678790d
Zobrazit plný text záznamu
2
Akademický článek
Comparative value of four measures of retention in expert care in predicting clinical outcomes and health care utilization in HIV patients.
Autor: Kelly R Reveles, Timothy R Juday, Matthew J Labreche, Eric M Mortensen, Jim M Koeller, Daniel Seekins, Christine U Oramasionwu, Mary Bollinger, Laurel A Copeland, Xavier Jones, Christopher R Frei
Publikováno v: PLoS ONE, Vol 10, Iss 3, p e0120953 (2015)
This study compared the ability of four measures of patient retention in HIV expert care to predict clinical outcomes. This retrospective study examined Veterans Health Administration (VHA) beneficiaries with HIV (ICD-9-CM codes 042 or V08) receiving
Externí odkaz: https://doaj.org/article/70568e0a85454915a86af283803992ef
Zobrazit plný text záznamu
9
Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non–small cell lung cancer treated at Veterans Health Administration facilities
Autor: Amanda Moore, Zohra Nooruddin, Kelly R Reveles, Paromita Datta, Lance Brannman, Ion Cotarla, Andrew Frankart, Tiernan Mulrooney, Xavier Jones, Christopher R Frei
Publikováno v: Journal of Clinical Oncology. 40:8526-8526
8526 Background: Evidence from the PACIFIC study and real-world data highlight the benefit of durvalumab in patients with stage III unresectable non-small cell lung cancer (UR-NSCLC). However, limited literature exists regarding disparities in durval
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b59caecc8a4209c0d63118fcc8608e7
https://doi.org/10.1200/jco.2022.40.16_suppl.8526
Zobrazit plný text záznamu
10
Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study
Autor: Kellie Ryan, Obiageri O Obodozie-Ofoegbu, Zohra Nooruddin, Amanda M. Moore, Alyssa Castillo, Kana Tai Lucero, Christopher R. Frei, Xavier Jones
Publikováno v: Blood. 138:340-340
Introduction Since the introduction of NAs in 2013, the treatment paradigm for CLL has changed significantly with the increased uptake of NAs for first line (1L) and refractory CLL. NA have introduced a personalized approach to CLL treatment that con
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39dfd127e8c2a1ac8e44e4a32e8a9a6a
https://doi.org/10.1182/blood-2021-146860
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje